Binary combinations of the N-nucleoside ribavirin (1-3-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) and the C-nucleoside analog selenazofurin (2-f8-D-ribofuranosylselenazole-4-carboxamide) or tiazofurin (2-(0-Dribofuranosylthiazole-4-carboxamide) were tested in vitro for activity against Venezuelan equine encephalomyelitis, Japanese encephalitis, yellow fever, Rift Valley fever, Korean hemorrhagic fever, and Pichinde viruses. The 50% effective dose for each compound alone or in a series of combinations was determined with a plaque reduction assay. Combinations of ribavirin and selenazofurin were synergistic against Venezuelan equine encephalomyelitis, Japanese encephalitis, yellow fever, and Pichinde viruses, with fractional inhibitory concentrations of 0.1, 0.2, 0.4, 0.4, respectively, but showed additive effects against Korean hemorrhagic fever and Rift Valley fever viruses. Combinations of ribavirin and tiazofurin were synergistic against yellow fever and Japanese encephalitis (fractional inhibitory concentrations, 0.41 and 0.48, respectively) but showed additive effects against Korean hemorrhagic fever virus. Combinations of selenazofurin and tiazofurin had additive effects against Japanese encephalitis, yellow fever, and Korean hemorrhagic fever viruses. The effect of combinations on cell toxicity was additive, both in monolayers of nondividing cells incubated under agar for the same period as the plaque assay and for rapidly dividing cells given short-term exposure (4 h), followed by determination of the proportion of surviving cells with a colony forming assay.
In the search for more effective antiviral compounds, we have screened numerous N-glycosyl and C-glycosyl nucleosides against selected members of the toga-, bunya-, and arenavirus families. The carboxamide nucleoside ribavirin (1-p-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) (8) was one of the most effective broad-spectrum agents tested. Limited structural modification of ribavirin did not improve its antiviral activity significantly; however, several analogs have shown comparable antiviral activity. Included were the novel selenazole carboxamide nucleoside selenazofurin (2-13-D-ribofuranosyl-selenazole-4-carboxamide) (19) , with a broad spectrum (13) and the closely related thiazole carboxamide nucleoside tiazofurin (2-1-D-ribofuranosly-thiazole-4-carboxamnide) (15, 18) , with a narrower spectrum but exceptionally active in vitro against Japanese encephalitis (JE), yellow fever (YF), and Hantaan virus, the causative agent of Korean hemorrhagic fever (KHF) (13) .
The structural similarities between ribavirin, selenazofurin, and tiazofurin and their known ability to inhibit IMP dehydrogenase prompted the in vitro evaluation of combinations to determine whether there would be potential benefits of such combinations over the use of a single compound. Binary Antiviral compounds. Ribavirin (1-P-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), tiazofurin (2-P-D-ribofuranosylthiazole-4-carboxamide), and selenazofurin (2-13-D-ribofuranosylselenazole-4-carboxamide, selenazole) were synthesized as previously described (18, 19, 22) .
Cells. All experiments were conducted with cells passaged 5 to 15 times in our laboratory. African green monkey kidney cells (Vero-76; ATCC CRL 1587) and a cloned line Vero E6 (Vero C1008; ATCC CRL-1586) were grown in Eagles minimum essential medium with Earle salts and 1 x nonessential amino acids supplemented with 10% fetal bovine serum (KC Biologicals, Inc., Lenexa, Kans.). Rhesus monkey kidney cells (LLC-MK2; ATCC CCL 7) were grown as described previously (13) . All cell cultures were tested weekly and found to be free of bacterial and mycoplasmal contamination (6) .
Viruses. Rift Valley fever virus (RVF) Zagazig 501 strain, Venezuelan equine encephalomyelitis virus (VEE) Trinidad donkey strain, Pichinde virus (PIC) CoAn 3739 strain, YF Asibi strain, JE Nakayama strain, and Hantaan virus, the etiological agent of KHF, HBL7990 strain, are described elsewhere (13) .
In (13) . Combination studies were designed, using the approach of Berenbaum (3), which is based on the dose of each compound causing a 50% response. To determine synergy, doseresponse assays of compound alone (to verify the ED50) and combinations of compounds at fixed ratios (typically, ratio of ED50 of compound A to ED50 of compound B, 10:1, 5:1, 2:1, 1:1, 1:2, 1:5, and 1:10) were performed. The molar concentration of each compound in a combination was calculated as follows. Beginning with the null hypothesis that the effects of the compounds in combination would be additive, an isobologram response surface was constructed based on the ED50s of each compound alone. Since virus inhibition is related among compounds by their ED50, the ratios for testing were selected based on the ratios of the ED50s by modeling in such a manner that each combination would contain four ED5so of activity. The stock solution and seven threefold serial dilutions were tested in triplicate to determine the dose-response curve for plaque reduction and were designed to yield from 0 to 100% response. The antiviral activity of combinations was evaluated by two methods. First, isobolograms (1, 2, 7, 12, 17) were constructed to convert the family of curves associated with each experiment into a two-dimensional plot, in which the concentration of each compound alone or in combination that produced the same response (a 50% plaque reduction) was graphed. Such plots yield an isobologram of constant responses.
Second, the fractional inhibitory concentration (FIC) (2, 3, 19) was calculated by using the following formula: FIC = [(ED50 of drug A in combination)/(ED50 of drug A alone)] + [(ED50 of drug B in combination)/(ED50 of drug B alone)]. The calculations were done by using the ED50 for each individual compound obtained from the experiment. Experiments with all viruses were repeated at least twice with lowpassage level cells and samples of virus from the same pool.
Toxicity. Toxicity determinations for stationary, nondividing monolayers were based on an assessment of cytopathic effects in treated cultures compared with those in control cells which were also maintained under agar overlay. Toxicity was determined in parallel with antiviral activity, using the same concentrations. Phase-contrast microscopy was used to evaluate morphological changes along with uptake of neutral red. Cultures were examined daily, including the day that plaques were read in the virus-challenged cultures. Acute toxicity in dividing cells was determined as follows: rapidly dividing subconfluent cells, subcultured 2 days previously, were removed with trypsin-EDTA, washed, and incubated with the compound (500 ,u.g/ml) or combinations as above for 4 h at 37°C, and the number of viable cells remaining was determined with a colony-forming assay in the standard growth media.
RESULTS
In vitro activity of ribavirin and selenazofurin in combination. The combination studies yielded a family of sigmoidal dose-response curves corresponding to each compound or fixed ratio of combinations. The partial FIC of each compound was calculated from the resulting ED50 obtained from each curve. Construction of the isobologram allows for a graphical representation of the family of curves as a single constant response line.
Combinations of selenazofurin with ribavirin were tested against six viruses that serve as models for other members of the toga-, bunya-, and arenavirus families. A representative experiment for each virus is shown in Fig. 1 . The three togaviruses tested possess significantly different virus properties within this family; however, all show similar responses to the antiviral compound tested. Against the alphavirus VEE and the flaviviruses YF and JE, ribavirin-selenazofurin combinations show significant deviation below the theoretical additive line (Fig. 1A, B , and C). VEE and JE were assayed in Vero-76 cells, and the FIC values for combinations (Table 1) show significant synergy at 0.1 and 0.21, respectively. The Asibi strain of YF does not form plaques well on Vero-76 cells, so assays were performed on LLC-MK2 cells. The isobolograms show a significant deviation below the additive effect line, although less than for VEE or JE. YF was inhibited at much lower concentrations of selenazofurin or ribavirin than was VEE or JE (10-fold), and significant synergy is still seen at a FIC of 0.43. For the togaand arenaviruses none of the compounds show antagonism at higher ratios of one compound compared with the other.
The isobologram for the arenavirus PIC assayed in Vero-76 cells (Fig. 1D) shows a deviation below the theoretically additive line (dashed), with a FIC of 0.4, indicating significant synergy (Table 1) .
The bunyavirus RVF assayed in Vero-76 cells showed no significant deviation below the additivity line, whereas combination studies with the bunyavirus KHF showed either no effect or antagonism (antagonism was seen when ribavirin Fig. 2A) show a marked deviation below the additivity line and are very similar to the patterns seen with selenazofurin-ribavirin combinations. The FIC was 0.48, near the arbitrary division point in our system (Table 1) . JE showed a profile that was essentially the same as that fcr selenazofurin-ribavirin (Fig. 2B) . The isobologram for KHF (Fig. 2C) shows no significant deviation below the additivity line.
In vitro activity of selenazofurin and tiazofurin in combinations. Selenazofurin-tiazofurin combinations tested against YF, JE, and KHF show an additive effect as judged both by the isobolograms (Fig. 3) and FICs near 1 (Table 1) .
In vitro toxicity of combinations. In vitro toxicity was determined by phase-contrast morphology and qualitative neutral red uptake by individual cells. No significant changes in morphology were observed in confluent monolayers of Vero-76, Vero E6, or LLC-MK2 cells for any of the binary combinations at any of the ratios tested. In each case, combinations were tested at each ratio up to a maximum combined FIC of 4 (Table 2). Morphology was followed up to the day that plaques were read. Neutral red uptake and sequestration into vacuoles were not affected. Assessment in dividing cells of toxicity from a 4-h exposure to the compounds showed no significant reduction in cell viability, as judged by the ability of cells to form colonies after compound exposure, with a plating efficiency assay.
DISCUSSION
Combinations of the antiviral drug ribavirin, an N-glycosyl nucleoside, and the closely related C-glycosyl nucleoside analogs tiazofurin and selenazofurin were tested against a number of RNA viruses representative of virus classes which cause notable human disease. In vitro studies were performed to determine the interactions of the compounds at various ratios relative to their individual ED50s. Combina Synergistic interactions could be explained if the two compounds had different sites of action. The inhibition of several cellular enzymes such as IMP dehydrogenase has been demonstrated for all three compounds (9) (10) (11) 20) , and this can be expected to alter nucleoside metabolism, with resulting changes in intracellular nucleotide pools. Ribavirin has been shown to accumulate in cells as the ribavirin triphosphate at concentrations approaching ATP levels (23). Selenazofurin and tiazofurin also form a NAD-like product which is a potent inhibitor of IMP dehydrogenase (5) . These changes in cellular metabolism are believed to be important in the cytotoxicity of the compounds, but the differences in virus response to identical conditions argue that these changes are unlikely to explain the antiviral activity. Although the number of viruses tested was small, the synergy exhibited by combinations of ribavirin and selenazofurin or tiazofurin against members of the togavirus and arenavirus families suggests that each compound is acting at a different site. The studies with selenazofurin and tiazofurin against JE, YE, and KHF showed no evidence of synergy; thus we could not find any evidence that these close structural analogs worked at different sites. The known alteration in intracellular nucleotide pools caused by these compounds may not be a sufficient explanation for their synergistic activity, since each family of viruses responded differently in its growth properties to the same concentration of compound. The viruses tested have significant differences in their mechanism of viral replication which may account for differences in compound sensitivity. The use of drug combinations may prove useful in the study of the replication mechanisms of these viruses.
Ribavirin, selenazofurin, and tiazofurin are known to be cytostatic for rapidly dividing cells (12, 14) . This inhibition appears to correlate with the inhibition of IMP dehydrogenase in resistant P388 cells (10) . The inhibition is reversible in most cases after removal of the compound. Cells in stationary culture, however, fail to show any evidence of morphological changes, including cytopathic effect, and remain viable as assayed by neutral red uptake even when cultured continuously in the presence of high concentrations of compound for 14 days. Similarly, no toxicity, as judged by VOL. 26, 1984 on August 27, 2017 by guest http://aac.asm.org/ Downloaded from the ability of cells to grow and form colonies (a test recognized as among the most sensitive), was found when dividing cells were incubated with the compounds for 4 h. Kirsi et al. in a companion study (12) also have shown that the toxicity for Vero cells of the three compounds in combination is additive, as judged by inhibition of subconfluent dividing cells. In our hands, Vero and Vero-76 cells responded identically to the inhibitory properties of these compounds. These toxicity findings are in opposition with those of studies based on cell division (unpublished data) in which all three compounds were found to inhibit cell replication in a dose-dependent manner. Published reports have shown that both tiazofurin and selenazofurin cause a reversible cell cycle arrest. Thus the toxicity appears to be classified as cytostatic and not cytocidal in nature. The use of such methods would thus measure a type of toxicity that may not be relevant to this study in which the virus is replicating in slowly dividing or stationary cells, and a cytostatic compound would have little effect. Definitive toxicity studies would probably be most appropriately done in vivo, along with in vitro studies with selected cell types more suitable for toxicity studies than for viral replication.
The demonstration of synergy between ribavirin and selenazofurin or tiazofurin is an important first step in the design of improved antiviral therapy. The patterns of interactions suggest starting combinations for in vivo studies and with certain viruses warn of the potential for antagonism at improper ratios of ribavirin-selenazofurin. The potential use of combinations to overcome single-compound shortcomings makes this an important approach to the treatment of serious human viral infections, and these studies provide the information required to design animal trials for these compounds.
